Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03556007 · ClinicalTrials.gov registry record · Phase 1
A Study of NKTR-358 (LY3471851) in Participants With Systemic Lupus Erythematosus (SLE)
A Phase 1 study, sponsored by Nektar Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT03556007 is a Phase 1 study that has completed, run by Nektar Therapeutics. The registered enrollment target is 48 participants.
The verdict
NCT03556007, a Phase 1 study, has completed, sponsored by Nektar Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the safety and tolerability of a study drug known as LY3471851 in participants with SLE. The study will last about 79 days for each participant.
Interventions
- DRUG Placebo
- DRUG LY3471851
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2018-04-18 |
| Est. Completion | 2019-08-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03556007
The ClinicalTrials.gov registry entry for NCT03556007 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nektar Therapeutics, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03556007 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03556007 about?
NCT03556007 is a clinical study titled "A Study of NKTR-358 (LY3471851) in Participants With Systemic Lupus Erythematosus (SLE)". The main purpose of this study is to evaluate the safety and tolerability of a study drug known as LY3471851 in participants with SLE. The study will last about 79 days for each participant.
What is the current status of trial NCT03556007?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2018-04-18. Estimated completion is 2019-08-29.
What interventions are being tested in trial NCT03556007?
The interventions under investigation include: Placebo (DRUG), LY3471851 (DRUG).
Who is sponsoring clinical trial NCT03556007?
This trial is sponsored by Nektar Therapeutics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.